Technical Analysis for TCRX - TScan Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -1.94% | |
| Wide Bands | Range Expansion | -1.94% | |
| Oversold Stochastic | Weakness | -1.94% | |
| NR7 | Range Contraction | -4.04% | |
| Wide Bands | Range Expansion | -4.04% | |
| Oversold Stochastic | Weakness | -4.04% | |
| Lower Bollinger Band Walk | Weakness | -3.81% | |
| Stochastic Reached Oversold | Weakness | -3.81% | |
| Wide Bands | Range Expansion | -3.81% | |
| Down 3 Days in a Row | Weakness | -3.81% |
| Alert | Time |
|---|---|
| Down 3% | about 3 hours ago |
| Fell Below Previous Day's Low | about 3 hours ago |
| Down 2 % | about 3 hours ago |
| New 52 Week Low | about 3 hours ago |
| Down 1% | about 4 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.69 |
| 52 Week Low | 4.03 |
| Average Volume | 224,625 |
| 200-Day Moving Average | 6.60 |
| 50-Day Moving Average | 5.21 |
| 20-Day Moving Average | 4.98 |
| 10-Day Moving Average | 4.99 |
| Average True Range | 0.35 |
| RSI (14) | 31.03 |
| ADX | 23.0 |
| +DI | 18.40 |
| -DI | 34.22 |
| Chandelier Exit (Long, 3 ATRs) | 5.18 |
| Chandelier Exit (Short, 3 ATRs) | 5.08 |
| Upper Bollinger Bands | 6.04 |
| Lower Bollinger Band | 3.92 |
| Percent B (%b) | 0.09 |
| BandWidth | 42.43 |
| MACD Line | -0.24 |
| MACD Signal Line | -0.10 |
| MACD Histogram | -0.1331 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.42 | ||||
| Resistance 3 (R3) | 4.42 | 4.33 | 4.37 | ||
| Resistance 2 (R2) | 4.33 | 4.25 | 4.33 | 4.35 | |
| Resistance 1 (R1) | 4.22 | 4.20 | 4.18 | 4.22 | 4.34 |
| Pivot Point | 4.13 | 4.13 | 4.10 | 4.13 | 4.13 |
| Support 1 (S1) | 4.02 | 4.05 | 3.98 | 4.02 | 3.90 |
| Support 2 (S2) | 3.93 | 4.00 | 3.93 | 3.89 | |
| Support 3 (S3) | 3.82 | 3.93 | 3.87 | ||
| Support 4 (S4) | 3.82 |
